Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Overview of attention for article published in BMC Public Health, July 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 63 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Lignes directrices unifiées de l’OMS sur la tuberculose : module 4 : traitement : traitement de la tuberculose pharmacorésistante

Cited by World Health Organization on 04 Oct 2023

The World Health Organization (WHO) is the directing and coordinating authority for health within the United Nations system.

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment

Cited by World Health Organization on 15 Dec 2022

The World Health Organization (WHO) is the directing and coordinating authority for health within the United Nations system.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.